A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation

drug protocol number
CINC424C2301
drug sponsor
Novartis
drug study
Ruxolitinib (INC424) (Jakavi)
drug trial site
KFSH&RC-R
drug status
Completed
drug phase